Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 3.3 EX-3.3
- 3.4 EX-3.4
- 4.5 EX-4.5
- 4.6 EX-4.6
- 4.7 EX-4.7
- 4.8 EX-4.8
- 4.9 EX-4.9
- 4.10 EX-4.10
- 4.11 EX-4.11
- 5.1 EX-5.1
- 8.1 EX-8.1
- 10.3 EX-10.3
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.1 EX-99.1
- 99.2 EX-99.2
- 99.3 EX-99.3
- 99.4 EX-99.4
- 99.5 EX-99.5
- 99.6 EX-99.6
- EX-FILING FEES Ex-filing Fees
- Download Excel data file
- View Excel data file
Associated filings
- 24 Jan 24 424B3 Prospectus supplement
- 24 Jan 24 424B3 Prospectus supplement
- 10 Jan 24 424B3 Prospectus supplement
- 5 Jan 24 EFFECT Notice of effectiveness
-
26 Dec 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 21 Nov 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 23 Oct 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 14 Sep 23 S-4 Registration of securities issued in business combination transactions
TVGN similar filings
Filing view
External links
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the use of our report dated September 14, 2023, with respect to the financial statements of Tevogen Bio Inc, included herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP | |
Philadelphia, Pennsylvania | |
December 22, 2023 |